NasdaqGS:FLDM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide.


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has Fluidigm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FLDM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.6%

FLDM

1.7%

US Life Sciences

2.7%

US Market


1 Year Return

-65.9%

FLDM

23.8%

US Life Sciences

9.1%

US Market

Return vs Industry: FLDM underperformed the US Life Sciences industry which returned 22.9% over the past year.

Return vs Market: FLDM underperformed the US Market which returned 8.4% over the past year.


Shareholder returns

FLDMIndustryMarket
7 Day-8.6%1.7%2.7%
30 Day84.0%7.3%4.5%
90 Day34.6%18.0%2.3%
1 Year-65.9%-65.9%24.0%23.8%11.5%9.1%
3 Year-7.8%-7.8%79.1%77.9%30.6%22.0%
5 Year-81.1%-81.1%128.8%125.8%57.2%39.5%

Price Volatility Vs. Market

How volatile is Fluidigm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fluidigm undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FLDM is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: FLDM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FLDM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FLDM is good value based on its PB Ratio (2.2x) compared to the US Life Sciences industry average (5.7x).


Next Steps

Future Growth

How is Fluidigm forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

10.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLDM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FLDM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FLDM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FLDM's revenue (12.8% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: FLDM's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FLDM is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Fluidigm performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FLDM is currently unprofitable.

Growing Profit Margin: FLDM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FLDM is unprofitable, and losses have increased over the past 5 years at a rate of -2% per year.

Accelerating Growth: Unable to compare FLDM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FLDM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.6%).


Return on Equity

High ROE: FLDM has a negative Return on Equity (-39.09%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fluidigm's financial position?


Financial Position Analysis

Short Term Liabilities: FLDM's short term assets ($82.4M) exceed its short term liabilities ($35.4M).

Long Term Liabilities: FLDM's short term assets ($82.4M) do not cover its long term liabilities ($113.4M).


Debt to Equity History and Analysis

Debt Level: FLDM's debt to equity ratio (38.1%) is considered satisfactory.

Reducing Debt: FLDM's debt to equity ratio has reduced from 137.4% to 38.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FLDM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FLDM has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 0.7% each year.


Next Steps

Dividend

What is Fluidigm's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FLDM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FLDM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FLDM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FLDM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FLDM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Chris Linthwaite (46yo)

3.58yrs

Tenure

US$3,713,055

Compensation

Mr. Stephen Christopher Linthwaite, also known as Chris, has been the President of Fluidigm Corporation since August 4, 2016. Mr. Linthwaite has been the Chief Executive Officer of Fluidigm Corporation si ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD3.71M) is above average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Linthwaite
President3.58yrsUS$3.71m0.29% $921.9k
Vikram Jog
Chief Financial Officer12.25yrsUS$1.39m0.15% $488.0k
Bradley Kreger
Senior Vice President of Global Operations2.08yrsUS$1.35m0.032% $102.4k
Nicholas Khadder
Senior VP3.92yrsUS$1.26m0.072% $226.5k
Colin McCracken
Chief Commercial Officer1.17yrsUS$1.96m0.020% $63.7k
Stephen Quake
Co-Founder & Chairman of Advisory Boardno datano datano data
Andrew Quong
Chief Science Officer0.92yrno datano data
Agnes Lee
Vice President of Investor Relationsno datano datano data
Mark Spearman
Senior Director of Corporate Communicationsno datano datano data
Angela Peters
Vice President of Global Human Resources2.83yrsno datano data

3.2yrs

Average Tenure

46yo

Average Age

Experienced Management: FLDM's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Linthwaite
President3.58yrsUS$3.71m0.29% $921.9k
Stephen Quake
Co-Founder & Chairman of Advisory Boardno datano datano data
Samuel Colella
Independent Chairman of the Board19.83yrsUS$200.46k0.31% $979.2k
Patrick Jones
Independent Director9.17yrsUS$163.47k0.027% $85.4k
Nicolas Barthelemy
Independent Director3.17yrsUS$163.22k0.19% $609.9k
Frank McCormick
Member of Advisory Board13.42yrsno datano data
Richard Zare
Member of Advisory Board19.42yrsno datano data
Howard Shapiro
Member of Advisory Board20.42yrsno datano data
James Berger
Member of Advisory Board17.92yrsno datano data
Carlos Paya
Independent Director3.17yrsUS$153.96k0.056% $175.9k

13.4yrs

Average Tenure

64.5yo

Average Age

Experienced Board: FLDM's board of directors are seasoned and experienced ( 13.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FLDM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Fluidigm Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fluidigm Corporation
  • Ticker: FLDM
  • Exchange: NasdaqGS
  • Founded: 1999
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$316.056m
  • Shares outstanding: 70.71m
  • Website: https://www.fluidigm.com

Number of Employees


Location

  • Fluidigm Corporation
  • 7000 Shoreline Court
  • Suite 100
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FLDMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2011
FLBDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2011

Biography

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 03:51
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.